To address the possibility of TriC‐dependent off‐target effects, investigate compensation mechanisms between ACSL proteins, and dissect specific biological roles for each ACSL member, future studies using genetic (knockdown or knockout) approaches to inhibit ACSL isozymes individually in myeloma cells are warranted. The gene discussed is MARVELD2; the disease is plasma cell myeloma.